Re-purposing, environmentally damaging HFC cryogenic chillers to environmentally inert natural refrigerants, for process chilling in the post Covid-19 pharmaceutical industry.

Over the next few months, UK pharmaceutical companies and institutes will need to develop anti-viral drugs to help overcome symptoms and vaccines to protect against and help combat the devastating effect of the COVID-19 virus.

Novel manufacturing techniques such as continuous processing, together with the safe low-temperature storage of vaccines will be required. These processes require temperatures between -50 and -80°C to operate correctly.

Currently, mechanical compressor-based low-temperature refrigeration systems use high cost \[£690/kg\] environmentally damaging HFC refrigerant gases. These gases under the UK-EU and UN climate change policies are legislated to be phased out over the next 10 years.

Likido currently manufactures low carbon, high-temperature industrial heat pumps that use a non-toxic, non-?ammable, environmentally inert, CFC/HFC free "natural working ?uid". Using Likido's experience in natural refrigerant technology and its unique two-stage compressors design, Likido over the next 3 months plan to fast track the manufacturing of a new range Cryochillers which will use HFC free "natural refrigerant gases that can operate down to -70°C and have global warming potential \[GWP\] of less than 50\.

This new innovation will ensure safe production and storage of medicines and vaccines at low temperatures and keep the UK's government commitment to climate change legislation.